Clinical trial · Observational
Treatment Response Prediction System of mCRC Patients Based on CTC
Treatment Response Prediction System of Metastatic Colorectal Cancer Based on Circulating Tumor Cells
NCT04917276CI-TRIAL-00052163unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study enrolling patients with metastatic colorectal cancer. Detecting CTC at different points in the treatment process. Descripting the molecular atlas of CTC in mCRC patients. Building and validating a response prediction system of mCTC patients.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Circulating Tumor Cell | — | UNRESOLVED | — |
| Colorectal Cancer Stage IV | Malignant Colorectal Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Circulating tumor cell | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Training Group
- description
- The training cohort that used to built the response prediction model
- interventionNames
- Diagnostic Test: Circulating tumor cell
- label
- Validation Group
- description
- The validation cohort that used to validate the response prediction model
- interventionNames
- Diagnostic Test: Circulating tumor cell
Primary outcomes (2)
- measure
- Sensitivity
- timeFrame
- 1 year
- description
- The sensitivity of the response prediction model
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * Age 18-80 years; histologically proven colorectal liver metastasis With liver-dominant disease (extrahepatic metastases limited to lung metastases) ECOG 0-1 A life expectancy of ≥ 3 months Adequate hematologic function: absolute neutrophil count (ANC)≥1.5×109/l, platelets≥75×109/l, and international normalized ratio (INR) ≤1.3 Adequate liver and renal function: total bilirubin ≤2.0 mg/dl, alanine aminotransferase, aspartate aminotransferase ≤ 5x upper limit of normal, and albumin≥2.5 g/dl, serum creatinine≤2.0 mg/dl Written informed consent for participation in the trial. Exclusion Criteria: * Other previous malignancy within 5 years Have metastases other than liver and lung metastases Receiving any treatment before first blood collection
References
Publications (0)
Data not yet available
No reference posted for this study.